DE69514794D1 - Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion - Google Patents

Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion

Info

Publication number
DE69514794D1
DE69514794D1 DE69514794T DE69514794T DE69514794D1 DE 69514794 D1 DE69514794 D1 DE 69514794D1 DE 69514794 T DE69514794 T DE 69514794T DE 69514794 T DE69514794 T DE 69514794T DE 69514794 D1 DE69514794 D1 DE 69514794D1
Authority
DE
Germany
Prior art keywords
apomorphin
treatment
dosage forms
erectile dysfunction
forms containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69514794T
Other languages
English (en)
Other versions
DE69514794T2 (de
Inventor
Ragab El-Rashidy
Jeremy P W Heaton
Alvaro Morales
Michael A Adams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University at Kingston
Pentech Pharmaceuticals Inc
Original Assignee
Queens University at Kingston
Pentech Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22868404&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69514794(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Queens University at Kingston, Pentech Pharmaceuticals Inc filed Critical Queens University at Kingston
Application granted granted Critical
Publication of DE69514794D1 publication Critical patent/DE69514794D1/de
Publication of DE69514794T2 publication Critical patent/DE69514794T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
DE69514794T 1994-04-22 1995-04-21 Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion Expired - Lifetime DE69514794T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23125094A 1994-04-22 1994-04-22
PCT/US1995/004897 WO1995028930A1 (en) 1994-04-22 1995-04-21 Dosage forms and method for ameliorating male erectile dysfunction

Publications (2)

Publication Number Publication Date
DE69514794D1 true DE69514794D1 (de) 2000-03-02
DE69514794T2 DE69514794T2 (de) 2000-07-27

Family

ID=22868404

Family Applications (3)

Application Number Title Priority Date Filing Date
DE2001199068 Active DE10199068I2 (de) 1994-04-22 1995-04-21 Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.
DE69534693T Expired - Fee Related DE69534693T2 (de) 1994-04-22 1995-04-21 Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz
DE69514794T Expired - Lifetime DE69514794T2 (de) 1994-04-22 1995-04-21 Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE2001199068 Active DE10199068I2 (de) 1994-04-22 1995-04-21 Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.
DE69534693T Expired - Fee Related DE69534693T2 (de) 1994-04-22 1995-04-21 Sublinguale Zusammensetzung enthaltend Apomorphine zur Diagnose der funktionellen Impotenz

Country Status (16)

Country Link
US (3) US5770606A (de)
EP (2) EP0758895B1 (de)
JP (1) JP3310982B2 (de)
KR (1) KR100374924B1 (de)
AT (2) ATE312609T1 (de)
AU (1) AU703608B2 (de)
CA (1) CA2188385C (de)
DE (3) DE10199068I2 (de)
DK (2) DK0978282T3 (de)
ES (2) ES2256999T3 (de)
GR (1) GR3033084T3 (de)
HK (2) HK1014239A1 (de)
LU (1) LU90856I2 (de)
NL (1) NL300072I1 (de)
PT (1) PT758895E (de)
WO (1) WO1995028930A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US20020165122A1 (en) * 1994-04-22 2002-11-07 Heaton Jeremy P. W. Method and compositions for the treatment or amelioration of female sexual dysfunction
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
AU751565B2 (en) * 1995-06-13 2002-08-22 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
EP0834308A1 (de) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmische Zubereitung zur Behandlung von Kurzsichtigkeit enthaltend einen Dopaminagonisten und Cyclodextrin
DE19652268C2 (de) * 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
DE69835288T2 (de) * 1997-05-19 2007-07-19 Zonagen, Inc., The Woodlands Kombinationstherapie zur modulation der humanen sexualreaktion
KR20010012995A (ko) * 1997-05-29 2001-02-26 모치다 에이 발기부전 치료제
US6103765A (en) * 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
JP2001509480A (ja) 1997-07-09 2001-07-24 アンドロソリューションズ，インク． 男性勃起機能不全を治療するための改良された方法及び組成物
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
EP1035833B1 (de) * 1997-12-02 2005-08-31 Archimedes Development Limited Zusammensetzungen zur nasalen verabreichung
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
AU2003204720B2 (en) * 1998-05-29 2006-06-29 Tap Pharmaceutical Products Inc. Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
WO2000012110A2 (en) 1998-08-26 2000-03-09 Queen's University At Kingston Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
US6087362A (en) * 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US7577475B2 (en) * 1999-04-16 2009-08-18 Cardiocom System, method, and apparatus for combining information from an implanted device with information from a patient monitoring apparatus
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
ES2256032T3 (es) * 1999-09-03 2006-07-16 Apbi Holdings, Llc Utilizacion de dapoxetina, un inhibidor selectivo de la recaptacion de serotonina, para el tratamiento de una disfuncion sexual.
BR0109515A (pt) 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
FR2813193B1 (fr) * 2000-08-25 2003-08-15 Pelvipharm Medicament pour le traitement des dysfonctions sexuelles par action sur le systeme nerveux central
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2429047A1 (en) 2000-11-15 2002-05-23 Tap Pharmaceutical Products, Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20020103105A1 (en) * 2000-11-22 2002-08-01 Brioni Jorge D. Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
EP1224933A1 (de) * 2001-01-19 2002-07-24 Sanofi-Synthelabo Neue Kombination mit Alfuzosin und Apomorphin als Aktiva
US20030022912A1 (en) * 2001-02-08 2003-01-30 Martino Alice C. Rapid-onset medicament for treatment of sexual dysfunction
US20030187011A1 (en) * 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
DE60308647T2 (de) * 2002-02-07 2007-08-09 Pharmacia Corp. Pharmazeutische darreichungsform zur mukosalen verabreichung
BR0308567A (pt) * 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
US20040138291A1 (en) * 2002-10-10 2004-07-15 Adams Michael A. Treatment of sexual dysfunction
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7943632B2 (en) * 2003-03-17 2011-05-17 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции
SI1633719T1 (sl) * 2003-06-17 2010-01-29 Janssen Pharmaceutica Nv Substituirani spirobenzazepini
TR201815853T4 (tr) 2005-10-12 2018-11-21 Besins Healthcare Sarl Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
JP2009523806A (ja) * 2006-01-20 2009-06-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （４ｒ）−１−［４−（２−クロロ−５−フルオロベンゾイル）アミノ−３−メトキシベンゾイル］−１，２，３，５−テトラヒドロ−スピロ［４ｈ−１−ベンズアゼピン−４，１’−［２］シクロペンテン］−３’−カルボン酸の新規固体形態物
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
KR20120042836A (ko) 2009-06-12 2012-05-03 아다지오 파마슈티컬즈 엘티디 설하 아포모르핀
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
KR20160108828A (ko) * 2013-11-11 2016-09-20 임팩스 라보라토리즈, 인코포레이티드 신속하게 붕괴되는 제형 및 사용 방법
CA2951912A1 (en) * 2014-06-12 2015-12-17 University Of Notre Dame Du Lac Composition and method for the treatment of neurological diseases and cerebral injury
CA3019769C (en) 2015-04-21 2021-10-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) * 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) * 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
PT689438E (pt) * 1993-03-26 2003-10-31 Franciscus Wilhelmus He Merkus Composicoes farmaceuticas para administracao intranasal de apomorfina

Also Published As

Publication number Publication date
KR970702041A (ko) 1997-05-13
KR100374924B1 (ko) 2003-07-22
JPH09512273A (ja) 1997-12-09
AU703608B2 (en) 1999-03-25
DE69534693D1 (de) 2006-01-19
WO1995028930A1 (en) 1995-11-02
DE69514794T2 (de) 2000-07-27
DK0978282T3 (da) 2006-04-10
LU90856I2 (fr) 2002-01-24
GR3033084T3 (en) 2000-08-31
ATE312609T1 (de) 2005-12-15
EP0758895B1 (de) 2000-01-26
EP0758895A4 (de) 1997-04-09
PT758895E (pt) 2000-05-31
US5985889A (en) 1999-11-16
HK1014239A1 (en) 1999-09-24
CA2188385A1 (en) 1995-11-02
US5770606A (en) 1998-06-23
ATE189121T1 (de) 2000-02-15
DE10199068I1 (de) 2003-06-05
HK1025742A1 (en) 2000-11-24
JP3310982B2 (ja) 2002-08-05
NL300072I1 (nl) 2002-02-01
DE10199068I2 (de) 2004-05-06
ES2143049T3 (es) 2000-05-01
EP0978282B1 (de) 2005-12-14
EP0758895A1 (de) 1997-02-26
CA2188385C (en) 2000-07-11
EP0978282A3 (de) 2000-06-07
US6200983B1 (en) 2001-03-13
DK0758895T3 (da) 2000-06-13
EP0978282A2 (de) 2000-02-09
AU2295895A (en) 1995-11-16
ES2256999T3 (es) 2006-07-16
DE69534693T2 (de) 2006-08-31

Similar Documents

Publication Publication Date Title
DE69514794T2 (de) Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
MX171177B (es) Composicion para desinfectar sustratos
DE69909818D1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE245416T1 (de) Neue fettanaloge zur behandlung von diabetes
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE3882775T2 (de) Zusammensetzung zur Behandlung von parodontaler Krankheit.
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.
DE3855159D1 (de) Thienotricyclen zur Behandlung von Erkrankungen der Bronchien
DE69504717D1 (de) Behandlung von organischen Verbindungen zur Reduzierung des Chlorgehaltes
DE3762526D1 (de) Hochkonzentrierte saeurezusammensetzungen fuer die behandlung von wasser und die reinigung von anlagen.
ATE81972T1 (de) Zusammensetzungen und verfahren zur behandlung von magengeschwueren.
DE69613418D1 (de) Behandlung von organischen Verbindungen zur Reduzierung des Chlorgehaltes
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE69214647T2 (de) Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz
DE69103294D1 (de) Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten.
ATE225664T1 (de) Verwendung von humanem alpha 1-sauren glycoprotein zur herstellung einer pharmazeutischen präparation
RU93058537A (ru) Применение атипамезола для лечения мужской сексуальной импотенции
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
DE69822628D1 (de) Zur vorbeugung oder behandlung von östrogenabhängigen krankheiten nützliche pyrrolo[2.1.5-cd]indolizin-derivate
ATE64683T1 (de) Zusammensetzung zur behandlung von haemorroiden.